Investor Overview

Corporate Profile
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem’s product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. The Company is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 2 study in refractory indolent Non-Hodgkin’s Lymphoma (iNHL) and is currently being evaluated in a Phase 3 registration trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Other clinical product candidates include focal adhesion kinase (FAK) inhibitors defactinib. Defactinib is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$2.48
Change (%) Stock is Up 0.13 (5.53%)
Volume402,332
Data as of 05/22/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
DateTitle 
05/18/17Verastem Announces Duvelisib Data Presentations at the 22nd Congress of the European Hematology Association
Abstract Highlighting Long-Term Follow Up Data from the DYNAMO® Study of Duvelisib in Patients with Double-Refractory Follicular Lymphoma Selected for Oral Presentation BOSTON--(BUSINESS WIRE)--May 18, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced an abstract featuring long-term follow up data from the DYNAMO® study evaluating duv... 
Printer Friendly Version
05/10/17Verastem Reports First Quarter 2017 Financial Results
BOSTON--(BUSINESS WIRE)--May 10, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the first quarter ended March 31, 2017 and provided an overview of certain corporate developments. “Following the presentation of positive data from the DYNAMO™ study of duvelisib in indolent non-Hodgkins Lymphoma (iNHL) at the Americ... 
Printer Friendly Version
05/03/17Verastem Announces Long Term Follow-up Data from the DYNAMO Study Selected for Oral Presentation at the 14th International Conference on Malignant Lymphoma
BOSTON--(BUSINESS WIRE)--May 3, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that an abstract describing long term follow-up data from the DYNAMO® study has been selected for oral presentation at the 14th International Conference on Malignant Lymphoma (ICML) being held June 14-17, 2017 in Lugano, Switzerland. DYNAMO is a Phase 2 clinical tr... 
Printer Friendly Version
05/02/17Verastem Appoints Eric K. Rowinsky to the Board of Directors
BOSTON--(BUSINESS WIRE)--May 2, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of Eric K. Rowinsky, MD to its Board of Directors. Dr. Rowinsky brings to Verastem nearly 30 years of experience in the development of cancer treatments, such as cetuximab (Erbitux) when he was Chief Medical Officer of ImClone Systems... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.